News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
680,385 Results
Type
Article (38854)
Company Profile (258)
Press Release (641273)
Section
Business (203647)
Career Advice (1979)
Deals (35350)
Drug Delivery (80)
Drug Development (80707)
Employer Resources (167)
FDA (16047)
Job Trends (14786)
News (344003)
Policy (32419)
Tag
Academia (2529)
Africa (712)
Alliances (49005)
Alzheimer's disease (1160)
Approvals (15976)
Arizona (178)
Artificial intelligence (86)
Asia (36871)
Australia (6004)
Bankruptcy (351)
Best Places to Work (11348)
Biosimilars (65)
Biotechnology (184)
Breast cancer (74)
C2C Services and Suppliers (78790)
California (2124)
Canada (1014)
Cancer (621)
Career advice (1649)
Cell therapy (150)
China (166)
Clinical research (63468)
Collaboration (194)
Colorado (87)
Compensation (112)
Connecticut (89)
COVID-19 (2500)
Cystic fibrosis (78)
Data (473)
Diabetes (98)
Diagnostics (6008)
Drug pricing (72)
Earnings (83702)
Employer resources (142)
Europe (78841)
Events (108099)
Executive appointments (184)
FDA (16352)
Florida (309)
Funding (187)
Gene therapy (105)
Georgia (68)
GLP-1 (526)
Government (4306)
Healthcare (18618)
Hotbed/Location (480946)
Illinois (274)
Indiana (155)
Infectious disease (2541)
Inflammatory bowel disease (93)
Interviews (306)
IPO (16218)
Job creations (3620)
Job search strategy (1413)
Kansas (94)
Layoffs (400)
Legal (7836)
Lung cancer (122)
Manufacturing (112)
Maryland (440)
Massachusetts (1738)
Medical device (13073)
Medtech (13078)
Mergers & acquisitions (19051)
Metabolic disorders (286)
Michigan (132)
Minnesota (226)
Neuroscience (1341)
New Jersey (652)
New York (666)
NextGen Class of 2024 (6482)
Non-profit (4457)
North Carolina (611)
Northern California (924)
Obesity (173)
Ohio (115)
Opinion (172)
Patents (80)
Pennsylvania (632)
People (55941)
Phase I (19663)
Phase II (27941)
Phase III (20888)
Pipeline (140)
Postmarket research (2550)
Preclinical (8340)
Radiopharmaceuticals (230)
Rare diseases (151)
Real estate (5884)
Regulatory (21294)
Research institute (2306)
Resumes & cover letters (347)
South America (1090)
Southern California (860)
Startups (3560)
Texas (275)
United States (9485)
Vaccines (493)
Washington State (266)
Weight loss (139)
Date
Last 7 days (652)
Last 30 days (2523)
Last 365 days (36547)
2024 (27489)
2023 (40074)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46541)
2018 (35019)
2017 (32111)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26346)
2012 (28570)
2011 (29263)
2010 (27328)
680,385 Results for "flugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
FluGen’s Intranasal M2SR Flu Vaccine, Co-Administered with High Dose Vaccine, in Older Adults Shows Superiority Over Flu Shot Alone
July 12, 2024
·
5 min read
BioMidwest
New Data Published in the Journal of Infectious Diseases Demonstrate FluGen’s M2SR Vaccine Candidate Substantially Enhances Mucosal & Serum Antibodies Against Drifted Influenza Strains
FluGen, Inc. today announced the publication of new data in the Journal of Infectious Diseases showing its investigational, high dose, intranasal H3N2 M2SR influenza vaccine candidate substantially enhanced mucosal and serum antibodies against drifted H3N2 influenza viruses.
November 9, 2022
·
4 min read
BioMidwest
FluGen Announces Completion of First Cohort in Age De-escalation Clinical Trial of M2SR Flu Vaccine Candidate in Pediatric Subjects Ages 6 Months to 17 Years
FluGen, Inc., today announced the completion of enrollment of the first cohort in an age de-escalation clinical trial of M2SR (M2 Deficient Single Replication) live virus vaccine, the company’s investigational supra-seasonal intranasal influenza (flu) vaccine, in volunteers ages 6 months to 17 years old.
September 7, 2022
·
4 min read
BioMidwest
FluGen to Present at the 40th Annual J.P. Morgan Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, today announced Boyd Clarke, Executive Chairman is scheduled to present at the 40th Annual J.P. Morgan Healthcare Conference.
January 5, 2022
·
1 min read
BioMidwest
FluGen to Present at Baird’s 2021 Global Healthcare Conference
FluGen, Inc., a clinical-stage vaccine company transforming vaccine efficacy in infectious respiratory diseases, announced management is scheduled to present at the Baird 2021 Global Healthcare Conference on Tuesday, September 14 at 5:30 PM E.T.
September 7, 2021
·
1 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Lophos Holdings Inc. Announces the Completion of Securities Purchase Agreement with ThreeD Capital Inc.
Lophos Holdings Inc. (CSE: MESC) (“Lophos” or the “Company”), a Canadian bioscience company focused on the cultivation and sale of Lophophora williamsii (“Peyote”) and ThreeD Capital Inc. (CSE: IDK) (OTCQB: IDKFF) (“ThreeD”), a Canadian-based venture capital firm focused on opportunistic investments in companies in the junior resources and disruptive technologies sectors, are pleased to announce the completion of its previously announced Securities Purchase Agreement (the “Agreement”).
June 20, 2024
·
4 min read
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials
Vivos Inc. (OTCQB: RDGL), Vivos Inc. filed the application for an Investigational Device Exemption (“IDE”).
June 28, 2024
·
4 min read
Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.®
Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has executed an asset purchase agreement with EndoGastric Solutions, Inc. for a total cash consideration of approximately $105 million.
July 1, 2024
·
18 min read
1 of 68,039
Next